The European Union has approved the sale of new Alzheimer’s drug with conditions
Brussels: The European Commission On Wednesday said that it has given formal approval LeakambiA long -awaited new remedies for the initial stage Alzheimer’s disease are to be sold under strict circumstances in the European Union.
The authority was awarded the treatment on Tuesday by Europe’s Medicine Watchdog based on a favorable decision, which supported treatment in the last November for a fixed category of patients after the initial misconception.
Lequmbi developed by US multinatily Biogen And a brand name of an active substance called Japanese-based EISAI, Lecnmab is used to treat adults with mild memory and cognitive problems, which is from the early stages of normal types of dementia.
The first such drug to be allowed in the European Union, the drug was approved to suit the “positive scientific assessment” European Medicines Agency“The Commission said in a statement.
EMA The Commission said, “The benefits of this drug have surpassed the risks until a particular population of patients with such a disease and as long as the risks are applied at least measures.”
“Therefore, the authority decision also determines a strict position on the use of lequembi, as well as the clear risk mitigation requirements,” it said.
EMA supported only the drug for low -risk patients with potential brain bleeding: who “only one copy or a copy of Apoe4”, a type of gene known as an important risk factor for Alzheimer’s.
Lecanemab has been performed for the first approved treatment by Alzheimer’s researchers and charity, which deal with the early stages of the disease rather than managing symptoms.
It works using antibodies that bind and clean the protein that is usually formed in the brain of people with Alzheimer’s, the most common type of dementia.
Treatment has been shown to reduce a fourth cognitive decline in people in the early stages of the disease.
Leqmbi, together with another Alzheimer’s drug Called Aduhelm, in 2023 received approval from the US Food and Drug Administration.
